Stereotactic Body Radiation Therapy (SBRT) for Stage I Non-Small Cell Lung Cancer (NSCLC): Outcomes by Fractionation, Tumor Stage and Location, and Patient Operability

11.7%, with chest wall toxicity constituting 5.8% vs 8.6% and pneumonitis 5.8% vs 3.0%, respectively. For central versus non-central lesions, 5-year actuarial local control, distant metastases-free, disease failure-free, and overall survivals (in %) were 79.0 vs 75.4, 49.5 vs 56.7, 37.2 vs 34.3, and 18.3 vs 20.3, respectively. At analysis, crude rates by lesion of local, lobar and regional nodal failure (in %) were 11.2, 4.1 and 13.5, respectively. There were no statistically significant differences in the failure rates between central and non-central lesions for all parameters. Conclusions: A decade’s experience with Lung SBRT using 50 Gy in 5 fractions reveals excellent local control. Patterns of cancer failure are mainly distant. Co-morbidities drive mortality in this population. This schedule is effective independent of tumor location in the lung, with minimal toxicities that are location-dependent. Author Disclosure: G.M. Videtic: None. C. Reddy: None. N. Woody: None. T. Djemil: None. K. Stephans: None.